Maniatis, AK;,
Casella, SJ;,
Nadgir, UM;,
Hofman, PL;,
Saenger, P;,
Chertock, ED;,
Aghajanova, EM;,
Korpal-Szczyrska, M;,
Vlachopapadopoulou, E;,
Malievskiy, O;,
Chaychenko, T;,
Cappa, M;,
Song, WJ;,
Mao, M;,
Mygind, PH;,
Smith, AR;,
Chessler, S;,
Komirenko, AS;,
Beckert, M;,
Aimee, D Shu,
Paul, S Thornton (2022) Purpose: The objectives of the ongoing, Phase
3, open-label extension trial enliGHten are to assess
Gaponov, D.P.,
Khafizov, T.N.,
Kochkina, K.V.,
Chernov, I.I.,
Enginoev, S.T.,
Shaposhnikova, E.I. (2022) -22) hours versus 1 (0-
3) hours, p=0,001; 5 (4-6) days versus 4 (
3-5) days, p=0,03) was shorter. In the open